Organon (OGN) Cash from Operations Growth (3y) (2023 - 2026)
Organon (OGN) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (3y) (Qtr) |
| 1 |
Gsk |
93,026,132.38 Bn |
93,026,127.42 Bn |
7.76 Bn |
73.44% |
| 2 |
Eli Lilly |
1,022.62 Bn |
1,017.34 Bn |
16.22 Bn |
45.52% |
| 3 |
Johnson & Johnson |
570.65 Bn |
548.59 Bn |
15.96 Bn |
-8.27% |
| 4 |
AbbVie |
398.73 Bn |
389.38 Bn |
10.78 Bn |
-2.98% |
| 5 |
Merck |
295.53 Bn |
289.88 Bn |
12.09 Bn |
43.03% |
| 6 |
Amgen |
186.30 Bn |
174.26 Bn |
5.87 Bn |
27.18% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
13.41% |
| 8 |
Pfizer |
146.09 Bn |
133.32 Bn |
-1.21 Bn |
29.22% |
| 9 |
Bristol Myers Squibb |
114.98 Bn |
104.53 Bn |
8.07 Bn |
-28.10% |
| 10 |
Organon |
3.49 Bn |
2.37 Bn |
783.00 Mn |
25.44% |
| Date | Value |
|---|
| Mar 31, 2026 |
25.44% |
| Dec 31, 2025 |
-19.17% |
| Sep 30, 2025 |
-5.92% |
| Jun 30, 2025 |
13.37% |
| Mar 31, 2025 |
-15.20% |
| Dec 31, 2024 |
102.45% |
| Sep 30, 2024 |
-27.37% |
| Jun 30, 2024 |
-9.30% |
| Mar 31, 2024 |
-61.19% |
| Dec 31, 2023 |
-6.39% |
| Sep 30, 2023 |
-6.57% |
| Jun 30, 2023 |
-66.73% |
| Mar 31, 2023 |
-46.56% |
